Fady Ibraham Malik Cytokinetics Inc (CYTK) insider trading activity

Fady Ibraham Malik is EVP Research & Development of CYTOKINETICS INC. Currently has a direct ownership of 118,920 shares of CYTK, which is worth approximately $6.62 Million. The most recent transaction as insider was on Feb 09, 2023, when has been sold 7,000 shares (Common Stock) at a price of $7.96 per share, resulting in proceeds of $55,720. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 119K

10.59% 3M change

23.6% 12M change

Total Value Held $6.62 Million

Fady Ibraham Malik Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 09 2023	BUY Exercise of conversion of derivative security	$55,720 $7.96 p/Share	7,000 Added 4.1%	163,589 Common Stock
Jan 12 2023	SELL Open market or private sale	$161,880 $40.47 p/Share	4,000 Reduced 2.49%	156,589 Common Stock
Dec 08 2022	SELL Open market or private sale	$145,120 $36.28 p/Share	4,000 Reduced 2.43%	160,589 Common Stock
Nov 10 2022	SELL Open market or private sale	$152,160 $38.04 p/Share	4,000 Reduced 2.38%	164,346 Common Stock
Oct 13 2022	SELL Open market or private sale	$1,017,135 $47.28 p/Share	21,513 Reduced 11.33%	168,346 Common Stock
Oct 13 2022	BUY Exercise of conversion of derivative security	$207,600 $9.65 p/Share	21,513 Added 10.18%	189,859 Common Stock
Sep 08 2022	SELL Open market or private sale	$1,115,420 $51.88 p/Share	21,500 Reduced 11.32%	168,346 Common Stock
Sep 08 2022	BUY Exercise of conversion of derivative security	$207,475 $9.65 p/Share	21,500 Added 10.17%	189,846 Common Stock
Jul 14 2022	SELL Open market or private sale	$933,745 $43.43 p/Share	21,500 Reduced 11.32%	168,346 Common Stock
Jul 14 2022	BUY Exercise of conversion of derivative security	$207,475 $9.65 p/Share	21,500 Added 10.17%	189,846 Common Stock
Jun 09 2022	SELL Open market or private sale	$873,330 $40.62 p/Share	21,500 Reduced 11.32%	168,346 Common Stock
Jun 09 2022	BUY Exercise of conversion of derivative security	$207,475 $9.65 p/Share	21,500 Added 10.17%	189,846 Common Stock
May 12 2022	SELL Open market or private sale	$525,072 $37.54 p/Share	13,987 Reduced 7.68%	168,084 Common Stock
May 12 2022	BUY Exercise of conversion of derivative security	$134,975 $9.65 p/Share	13,987 Added 7.13%	182,071 Common Stock
Apr 07 2022	SELL Open market or private sale	$985,642 $42.58 p/Share	23,148 Reduced 12.1%	168,084 Common Stock
Apr 07 2022	BUY Exercise of conversion of derivative security	$138,888 $6.0 p/Share	23,148 Added 10.8%	191,232 Common Stock
Mar 10 2022	SELL Open market or private sale	$1,015,543 $37.82 p/Share	26,852 Reduced 13.77%	168,084 Common Stock
Mar 10 2022	BUY Exercise of conversion of derivative security	$161,112 $6.0 p/Share	26,852 Added 12.11%	194,936 Common Stock
Mar 07 2022	SELL Payment of exercise price or tax liability	$365,206 $36.83 p/Share	9,916 Reduced 5.57%	168,084 Common Stock
Mar 02 2022	SELL Payment of exercise price or tax liability	$188,301 $37.63 p/Share	5,004 Reduced 3.27%	148,000 Common Stock
Mar 02 2022	BUY Grant, award, or other acquisition	-	30,000 Added 14.42%	178,000 Common Stock
Feb 28 2022	SELL Payment of exercise price or tax liability	$122,137 $35.32 p/Share	3,458 Reduced 2.21%	153,004 Common Stock
Feb 16 2022	BUY Grant, award, or other acquisition	-	7,148 Added 4.37%	156,462 Common Stock
Dec 09 2021	SELL Open market or private sale	$1,064,267 $36.49 p/Share	29,166 Reduced 16.34%	149,314 Common Stock
Dec 09 2021	BUY Exercise of conversion of derivative security	$183,746 $6.3 p/Share	29,166 Added 14.49%	172,053 Common Stock

Also insider at

RCKT

ROCKET PHARMACEUTICALS, INC. Healthcare

FIM